Omeros Return on Tangible Equity 2010-2024 | OMER
Current and historical return on tangible equity values for Omeros (OMER) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Omeros Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $-0.13B | $-0.15B | 142.93% |
| 2024-06-30 | $-0.14B | $-0.13B | 238.30% |
| 2024-03-31 | $-0.12B | $-0.07B | 543.82% |
| 2023-12-31 | $-0.12B | $-0.03B | -1275.68% |
| 2023-09-30 | $0.02B | $-0.01B | 54.05% |
| 2023-06-30 | $0.04B | $0.02B | 141.38% |
| 2023-03-31 | $0.05B | $0.06B | 303.23% |
| 2022-12-31 | $0.05B | $0.09B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.05B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.03B | -280.14% |
| 2022-03-31 | $0.20B | $-0.01B | -160.00% |
| 2021-12-31 | $0.19B | $0.02B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.26B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.25B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.22B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.12B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.09B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.16B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.11B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.14B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.13B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $-0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $-0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.557B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.977B | 28.52 |
| Boston Scientific (BSX) | United States | $155.488B | 41.98 |
| Stryker (SYK) | United States | $147.446B | 31.70 |
| EssilorLuxottica (ESLOY) | France | $140.780B | 0.00 |
| Medtronic (MDT) | Ireland | $112.764B | 16.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.084B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.818B | 29.12 |
| GE HealthCare Technologies (GEHC) | United States | $42.113B | 20.51 |
| Agilent Technologies (A) | United States | $39.025B | 25.86 |
| ResMed (RMD) | United States | $34.189B | 26.33 |
| Terumo (TRUMY) | Japan | $26.310B | 37.41 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 16.80 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.630B | 12.95 |
| Insulet (PODD) | United States | $20.222B | 86.57 |
| Baxter (BAX) | United States | $17.074B | 12.34 |
| Sunny Optical Technology (SNPTF) | China | $11.331B | 0.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.245B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.513B | 35.65 |
| Bio-Rad Laboratories (BIO) | United States | $8.001B | 27.70 |
| Demant (WILYY) | Denmark | $7.946B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.621B | 13.06 |
| Prestige Consumer Healthcare (PBH) | United States | $4.200B | 20.05 |
| ICU Medical (ICUI) | United States | $3.995B | 38.03 |
| Envista Holdings (NVST) | United States | $3.693B | 29.38 |
| Perrigo (PRGO) | Ireland | $3.443B | 10.14 |
| Haemonetics (HAE) | United States | $3.188B | 15.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.921B | 19.69 |
| QuidelOrtho (QDEL) | United States | $2.760B | 23.18 |
| LeMaitre Vascular (LMAT) | United States | $2.269B | 55.15 |
| Neogen (NEOG) | United States | $2.178B | 25.10 |
| AtriCure (ATRC) | United States | $1.914B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.484B | 25.90 |
| InMode (INMD) | Israel | $1.320B | 11.03 |
| BioLife Solutions (BLFS) | United States | $1.276B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.180B | 8.43 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.997B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.938B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.930B | 14.27 |
| Evolus (EOLS) | United States | $0.926B | 0.00 |
| CeriBell (CBLL) | United States | $0.828B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.689B | 0.00 |
| Valneva SE (VALN) | France | $0.643B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.529B | 22.95 |
| Owens & Minor (OMI) | United States | $0.494B | 3.86 |
| Surmodics (SRDX) | United States | $0.492B | 0.00 |
| SNDL (SNDL) | Canada | $0.462B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.373B | 0.00 |
| ZimVie (ZIMV) | United States | $0.368B | 30.98 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.349B | 0.00 |
| Cerus (CERS) | United States | $0.323B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.321B | 58.60 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.52 |
| Sanara MedTech (SMTI) | United States | $0.309B | 0.00 |
| Quanterix (QTRX) | United States | $0.292B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Biote (BTMD) | United States | $0.260B | 5.69 |
| Canopy Growth (CGC) | Canada | $0.250B | 0.00 |
| Zynex (ZYXI) | United States | $0.236B | 49.40 |
| Sanuwave Health (SNWV) | United States | $0.231B | 3.24 |
| Brainsway (BWAY) | Israel | $0.212B | 112.80 |
| High Tide (HITI) | Canada | $0.209B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.206B | 15.39 |
| MacroGenics (MGNX) | United States | $0.181B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.174B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.163B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.140B | 17.51 |
| Jin Medical (ZJYL) | China | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.112B | 0.00 |
| Fonar (FONR) | United States | $0.091B | 12.79 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| InterCure (INCR) | Israel | $0.075B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.067B | 0.00 |
| Exagen (XGN) | United States | $0.067B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.058B | 30.00 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Hongchang (HCIL) | China | $0.051B | 0.00 |
| MariMed (MRMD) | United States | $0.050B | 0.00 |
| United-Guardian (UG) | United States | $0.050B | 14.22 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| INLIF (INLF) | $0.040B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.031B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |